336 results on '"Fukuhara, Suguru"'
Search Results
2. Loss of or decrease in CD30 expression in four patients with anaplastic large cell lymphoma after brentuximab vedotin-containing therapy
3. Heterogeneity or change in cell of origin in diffuse large B-cell lymphomas determined using hans algorithm
4. Clinicopathological differences between T-lymphoblastic leukemia/lymphoma, early T-precursor lymphoblastic leukemia/lymphoma, and mixed-phenotype acute leukemia with T lineage: An analysis of 41 adult cases
5. Romidepsin-induced durable remission for relapsed nodal peripheral T-cell lymphoma with T follicular helper phenotype after allogeneic hematopoietic cell transplantation
6. Long-term safety profile of tirabrutinib: final results of a Japanese Phase I study in patients with relapsed or refractory B-cell malignancies
7. Pathogenesis of Gastrointestinal Follicular Lymphomas: Consideration Based on Histopathology and Endoscopic Findings
8. Interim PET‐guided ABVD or ABVD/escalated BEACOPP for newly diagnosed advanced‐stage classic Hodgkin lymphoma (JCOG1305).
9. Usefulness of hematopoietic progenitor cell monitoring to predict autologous peripheral blood stem cell harvest timing: A single-center retrospective study
10. Different phenotype relapse of myeloid/lymphoid neoplasms with FGFR1 rearrangement with long remission
11. Rituximab and Alemtuzumab for Chronic Lymphocytic Leukemia: Clinical Pharmacology and Therapeutic Results
12. Clinicopathological characteristics of diffuse large B-cell lymphoma involving small and large intestines: an analysis of 126 patients
13. Mucosa-associated lymphoid tissue lymphoma with t(11;18)(q21;q21) translocation: long-term follow-up results
14. Comparison of clinicopathologic characteristics of gastric follicular lymphomas and duodenal follicular lymphomas
15. Multiple myeloma with IGH-FGFR3 rearrangement progressing as testicular plasmacytoma during carfilzomib treatment
16. CD3+ CD56+ EBER1+ atypical extraosseous plasmacytoma of the nasal cavity
17. Diagnostic clues of BCL2-negative, faint, or controversial follicular lymphomas: A study of 103 cases
18. Diffuse large B-cell lymphoma with composite germinal center and non-germinal center types: A report of two cases
19. Long-term safety profile of tirabrutinib: final results of a Japanese Phase I study in patients with relapsed or refractory B-cell malignancies
20. A First-in-Human Phase I Study of CTX-712 in Patients with Advanced, Relapsed or Refractory Malignant Tumors - Hematologic Malignancies Dose Escalation Cohort
21. Interim PET-Guided ABVD or ABVD/Escalated BEACOPP for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma (JCOG1305, INNOVATE-HL study)
22. A Practice-Oriented Genome Profiling Study with the Novel Halo-Shape Annealing and Defer-Ligation Enrichment (HANDLE) System : HM-Screen-JAPAN02
23. Distribution of malignant lymphomas in the anterior mediastinum: a single-institution study of 76 cases in Japan, 1997–2016
24. Prognosis of patients with peripheral T cell lymphoma who achieve complete response after CHOP/CHOP-like chemotherapy without autologous stem cell transplantation as an initial treatment
25. Influence of the watch and wait strategy on clinical outcomes of patients with follicular lymphoma in the rituximab era
26. Prognostic implications of histologic grade and intensity of Bcl-2 expression in follicular lymphomas undergoing rituximab-containing therapy
27. Classical Hodgkin lymphoma primary refractory to brentuximab vedotin, with transformation to CD30-positive diffuse large B-cell lymphoma
28. Clinical features and outcomes of 139 Japanese patients with Hodgkin lymphoma
29. Clinicopathological prognostic factors of 24 patients with B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma
30. Final analysis of randomized phase II study optimizing melphalan, prednisolone, bortezomib in multiple myeloma ( JCOG1105 )
31. MO10-2 Emerging molecular targets in AML: IDH1/2- and menin-related mutations (HM-SCREEN-JAPAN01)
32. Feasibility and clinical utility of comprehensive genomic profiling of hematological malignancies
33. CD3-and CD20-negative extramedullary non-Hodgkin leukemia/lymphoma: a histopathological study of 118 cases
34. A first-in-human phase I study of CTX-712 in patients with advanced, relapsed or refractory malignant tumors.
35. The outcome of watchful waiting in patients with previously treated follicular lymphoma
36. Successful full-dose DeVIC therapy in a patient with advanced-stage extranodal natural killer/T-cell lymphoma refractory to l-asparaginase
37. The role of surveillance computed tomography in patients with follicular lymphoma
38. Hematologic Malignancies (HM)-Screen-Japan 01: A Mutation Profiling Multicenter Study on Patients with Acute Myeloid Leukemia
39. Properties and Distribution of IDH-1/2 Mutations in Acute Myeloid Leukemia By the Comprehensive Genomic Analysis
40. Genomic Analysis of NPM1 Mutation and KMT2A(MLL)-Rearrangement/Amplification in Japanese Patients with Acute Myeloid Leukemia: Hematologic Malignancies (HM)-Screen-Japan 01
41. Clinical Significance of FLT3 Mutations in a Comprehensive NGS Multicenter Study of AML: HM-Screen-Japan 01
42. Outcomes of hematopoietic cell transplantation for transformed follicular lymphoma
43. Diagnostic utility and prognostic significance of the Ki‐67 labeling index in diffuse large B‐cell lymphoma transformed from follicular lymphoma: a study of 76 patients
44. Clinicopathological features of classical Hodgkin lymphoma in patients ≥40 years old, with special reference to composite cases
45. Incidental detection of malignant lymphoma in subjects in a cancer surveillance programme
46. Intrafollicular classical Hodgkin lymphoma mimicking nodular lymphocyte predominant Hodgkin lymphoma: A report of two cases
47. Clinicopathological analysis of primary refractory diffuse large B‐cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone chemoimmunotherapy
48. Clinicopathological factors and tumor microenvironment markers predicting watch‐and‐wait discontinuation in 82 patients with follicular lymphoma
49. CD5-negative blastoid variant mantle cell lymphoma: a diagnostic dilemma
50. CDKN1C‐mediated growth inhibition by an EZH1/2 dual inhibitor overcomes resistance of mantle cell lymphoma to ibrutinib
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.